Current status of liver transplantation for hepatitis B virus.
The management of hepatitis B in liver transplantation has evolved significantly over the past 2 decades. Introduction of hepatitis B immune globulin and subsequently nucleos(t)ide analogues has revolutionized transplantation for hepatitis B virus (HBV), increasing survival for patients transplanted for this indication. With the availability of new and potent antivirals for HBV, the need for liver transplant should continue to decrease in the coming years. Moreover, the newer antivirals with high resistance barriers will allow effective long-term viral prophylaxis and therefore, prevention of recurrence.
Center for Liver Transplantation, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Corinne
C
Buchanan
Tram T
TT
Tran
D000998:Antiviral Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006515:Hepatitis B virus / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification*; D019694:Hepatitis B, Chronic / Q000150:complications / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D007372:Interferons / Q000627:therapeutic use; D019259:Lamivudine / Q000627:therapeutic use; D016031:Liver Transplantation; D008297:Male; D055502:Secondary Prevention; D016896:Treatment Outcome; D019562:Viral Load
D000998:Antiviral Agents; D007136:Immunoglobulins; D007166:Immunosuppressive Agents; D019259:Lamivudine; D007372:Interferons; C045213:hepatitis B hyperimmune globulin